Table 1 Virological characteristics of patients with chronic hepatitis B who provided HBV inocula

From: Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma

Inoculum

Patient age (years)/sex

HBV DNA(IU/ml) a

HBV genotype b

HBsAg c

HBeAg c

Anti-HBe c

Anti-HBc c

HIV RNA d

Anti-HCV e

NL01

58/M

2.7 × 107

A

pos

pos

neg

pos

neg

neg

NL02

35/F

1.1 × 108

C

pos

n.a.

n.a.

pos

neg

neg

NL03

33/M

5.8 × 108

E

pos

pos

n.a.

pos

neg

neg

  1. Abbreviations: anti-HBc, antibodies to HBV core antigen; anti-HBe, antibodies to HBeAg; anti-HCV, antibodies to hepatitis C virus; F, female; HBeAg, HBV e antigen; HBsAg, HBV surface antigen; IU, international units; M, Male; n.a., not available.
  2. aDetermined by COBAS Ampliprep/TaqMan HBV Test (sensitivity 20 IU/ml) Roche Diagnostics, Laval, Quebec, Canada.
  3. bAssayed by in-house PCR with HBV S gene-specific primers (forward primer: 5′-GCCTCATTTTGTGGGTCACCATA-3' and reverse primer: 5′-ATAACTGAAAGCCAAACAGTGGG-3') and bidirectional sequencing of the resulting 1115-bp amplicons.
  4. cDetermined by ARCHITECT immunoassays from Abbott Diagnostics, Mississauga, Ontario, Canada.
  5. dTested by Abbott Real Time HIV-1 assay m2000 (sensitivity 75–107 virus copies/ml), Abbot Diagnostics, Mississauga, Ontario, Canada.
  6. eDetermined by COBAS Amplicor HCV v2.0 (sensitivity 50–60 IU/ml), Roche Diagnostics, Laval, Quebec, Canada.
Back to article page